Covered recipient · General Payments record
PAUL J ORCHARD
Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology
General Payments · PY2018–2024
$83,729.18
- Reported across 38 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $23,558.00 | 4 |
| Travel and Lodging | $726.29 | 3 |
| Food and Beverage | $411.83 | 4 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $20,594.12 | 6 |
| JAZZ PHARMACEUTICALS INC. | $3,500.00 | 1 |
| Eli Lilly and Company | $450.00 | 1 |
| Orchard Therapeutics North America | $152.00 | 3 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (11)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Eli Lilly and Company | $450.00 | 10/31/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1135285719 | CMS |
| GENZYME CORPORATION | $259.83 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139616438 | CMS |
| GENZYME CORPORATION | $301.39 | 11/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1139616440 | CMS |
| GENZYME CORPORATION | $328.38 | 11/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1139616442 | CMS |
| GENZYME CORPORATION | $96.52 | 11/14/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1139616444 | CMS |
| GENZYME CORPORATION | $17,946.00 | 11/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1139616446 | CMS |
| GENZYME CORPORATION | $1,662.00 | 12/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1139616450 | CMS |
| JAZZ PHARMACEUTICALS INC. | $3,500.00 | 07/28/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1150228591 | CMS |
| Orchard Therapeutics North America | $58.00 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132968044 | CMS |
| Orchard Therapeutics North America | $24.00 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132968046 | CMS |
| Orchard Therapeutics North America | $70.00 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132968048 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.